engleski

Antiphospholipid antibodies - A predictor of coronary heart disease

Antiphospholipid syndrome (APS) is characterized by occurrence of vascular thrombosis and/or obstetric pathology with a positive antiphospholipid antibody titer (aPL). According to consensus criteria, APS includes cardiolipin antibodies (aCL), lupus anticoagulant (LA) and anti-beta2 glycoprotein- I (anti-â2GPI). To confirm the diagnosis it is required to have, along with clinical manifestations, at least two aPL positive titer in the span of 12 weeks. APS pathology and problems related to pregnancy and vascular thrombosis are well-researched entities that are successfully treated. It is of great importance to show that aPL has impact on the cardiovascular system and brought aPL into connection with development of early atherosclerotic coronary artery disease, valvular disease, dilated cardiomyopathy, pulmonary hypertension and pulmonary thromboembolism. This review paper shows the significance of aPL in the development of coronary heart disease and its impact on early and late complications of disease.

Antiphospholipid syndrome; Antiphospholipid antibodies; Coronary heart disease

nije evidentirano